This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

Zacks' proprietary stock-rating model, the Zacks Rank, which leverages earnings estimate revisions, has demonstrated significant historical outperformance, with its #1 (Strong Buy) stocks yielding an average annual return of 23.75% over 26 of the last 32 years. Tenet Healthcare (THC) is presented as a current example, recently added to the #1 list on July 25, 2025, exhibiting strong fundamentals: nine analysts revised FY2025 estimates higher, boosting the consensus to $15.54/share, alongside a 31.2% average earnings surprise and projected 30.8% earnings growth. This, combined with THC's 14.1% stock gain over the past four weeks against the S&P 500's 2%, positions it as a noteworthy consideration for investors.

Analysis

Tenet Healthcare (THC) is exhibiting strong bullish signals, primarily driven by a significant positive trend in analyst earnings estimates for fiscal year 2025. Over the past 60 days, nine analysts have revised their earnings forecasts upward, boosting the Zacks Consensus Estimate by $2.81 to $15.54 per share. This upward revision in profitability expectations is supported by a forecast for 30.8% earnings growth for the current fiscal year, alongside a projected 2.4% increase in sales. The company has a demonstrated history of exceeding expectations, reflected by an average positive earnings surprise of 31.2% in recent quarters. This fundamental strength is mirrored in its market performance, with THC's stock gaining 14.1% over the last four weeks, substantially outperforming the S&P 500's 2% gain in the same period.

Key Decisions for Investors

• Given the powerful combination of upward earnings estimate revisions, strong projected earnings growth, and significant price momentum, investors may view THC as a compelling long opportunity.
• The core of the bullish thesis rests on continued positive analyst sentiment, making it critical to monitor for any potential negative revisions in future earnings estimates.
• Considering the stock's recent 14.1% gain, investors should be aware that the position reflects a momentum strategy, which could attract further institutional capital but also carries volatility risk if the trend falters.